Article Navigation
- < Previous
- Next >
Journal Article
Get access
Carola Berking Writing - original draft, Writing - review & editing Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany; 2Comprehensive Cancer Center Erlangen – European Metropolitan Region Nürnberg Uniklinikum Erlangen, FAU, Erlangen , Germany Correspondence: Carola Berking. Email: Carola.Berking@uk-erlangen.de Search for other works by this author on: Oxford Academic
https://orcid.org/0000-0003-0229-8931 British Journal of Dermatology, Volume 188, Issue 2, February 2023, Page 166, https://doi.org/10.1093/bjd/ljac087
Published:
17 November 2022
Article history
Received:
31 October 2022
Accepted:
12 November 2022
Published:
17 November 2022
Corrected and typeset:
13 January 2023
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
Carola Berking, Update on the management of Bowen disease with a focus on patients’ needs, British Journal of Dermatology, Volume 188, Issue 2, February 2023, Page 166, https://doi.org/10.1093/bjd/ljac087
Close
Search
Close
Search
Advanced Search
Search Menu
Extract
https://doi.org/10.1093/bjd/ljac087
It is 110 years ago now that the Boston Professor of Dermatology John Templeton Bowen described a ‘chronic atypical epithelial proliferation’ as a precancerous dermatosis in two patients.1,2 Two years later his famous colleague, the French dermatologist Jean Darier, suggested naming this disease, which Darier described in his 1920 text book as ‘Dyskeratosis lenticularis et discoides’, after the first author.1 The term Bowen disease (BD) has continued to be used for this special type of squamous cell carcinoma (SCC) in situ. BD is characterized by full-thickness epidermal atypia with large, round cells with pleomorphic and hyperchromatic nucleus and clear cytoplasm, mitotic figures and possible adnexal involvement.3 It is different from common actinic keratosis (AK) with the exception of bowenoid AK (AK type III). Clinically, BD commonly presents as slow-growing, well-demarcated, erythematous, scaly patches or plaques and progression to Bowen carcinoma (invasive SCC) has been reported in up to 5% of cases. Adequate therapy is necessary and includes surgical treatment methods, ablative interventions, radiotherapy and topical agents, such as 5-fluorouracil, imiquimod and photodynamic therapy.
You do not currently have access to this article.
Download all slides
Sign in
Get help with access
-
British Association of Dermatologists members
-
All other society members
Sign in through society site
Personal account
- Sign in with email/username & password
- Get email alerts
- Save searches
- Purchase content
- Activate your purchase/trial code
- Add your ORCID iD
Sign in Register
Institutional access
- Sign in through your institution
- Sign in with a library card
- Sign in with username/password
- Recommend to your librarian
Institutional account management
Sign in as administrator
Get help with access
Institutional access
Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:
IP based access
Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.
Sign in through your institution
Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.
- Click Sign in through your institution.
- Select your institution from the list provided, which will take you to your institution's website to sign in.
- When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
- Following successful sign in, you will be returned to Oxford Academic.
If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.
Sign in with a library card
Enter your library card number to sign in. If you cannot sign in, please contact your librarian.
Society Members
Society member access to a journal is achieved in one of the following ways:
Sign in through society site
Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:
- Click Sign in through society site.
- When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
- Following successful sign in, you will be returned to Oxford Academic.
If you do not have a society account or have forgotten your username or password, please contact your society.
Sign in using a personal account
Some societies use Oxford Academic personal accounts to provide access to their members. See below.
Personal account
A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.
Some societies use Oxford Academic personal accounts to provide access to their members.
Viewing your signed in accounts
Click the account icon in the top right to:
- View your signed in personal account and access account management features.
- View the institutional accounts that are providing access.
Signed in but can't access content
Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.
Institutional account management
For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.
Purchase
Subscription prices and ordering for this journal
Purchasing options for books and journals across Oxford Academic
Short-term Access
To purchase short-term access, please sign in to your personal account above.
Don't already have a personal account? Register
Update on the management of Bowen disease with a focus on patients’ needs - 24 Hours access
EUR €58.00
GBP £50.00
USD $62.00
Rental
This article is also available for rental through DeepDyve.
Advertisem*nt intended for healthcare professionals
Citations
Views
420
Altmetric
More metrics information
Metrics
Total Views 420
278 Pageviews
142 PDF Downloads
Since 11/1/2022
| Month: | Total Views: |
|---|---|
| November 2022 | 6 |
| January 2023 | 44 |
| February 2023 | 148 |
| March 2023 | 79 |
| April 2023 | 22 |
| May 2023 | 9 |
| June 2023 | 8 |
| July 2023 | 14 |
| August 2023 | 7 |
| September 2023 | 2 |
| October 2023 | 4 |
| November 2023 | 4 |
| December 2023 | 5 |
| January 2024 | 10 |
| February 2024 | 40 |
| March 2024 | 5 |
| April 2024 | 3 |
| May 2024 | 10 |
Citations
Powered by Dimensions
Altmetrics
Email alerts
Article activity alert
Advance article alerts
New issue alert
Receive exclusive offers and updates from Oxford Academic
See also
-
Commentary
- British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022
Citing articles via
Google Scholar
-
Latest
-
Most Read
-
Most Cited
Advertisem*nt intended for healthcare professionals
